All the news Showing 10 of 18 articles from: NAFLDGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition STAT / 19 February 2019 Gilead’s Liver-Drug Setback Clouds $35 Billion Dream Bloomberg / 13 February 2019 Gilead rocked by phase 3 failure of selonsertib in NASH Fierce BioTech / 13 February 2019 A Big, Fatty Opportunity for Big Pharma Wall Street Journal / 18 January 2019 Take Home from NASH-TAG: On the precipice of the fatty liver pipeline Healio / 18 January 2019 Why has liver disease in Britain reached 'almost epidemic' proportions? Daily Telegraph / 17 December 2018 Novel Thyroid Beta Receptor Agonist Cut LDL-C in NAFLD Patients MedPage Today Gastroenterology / 14 November 2018 Cirius Therapeutics Reports Positive Data for MSDC-0602K in Interim Analysis of Phase 2b Clinical Trial in NASH Patients with Fibrosis Cirius Therapeutics press release / 26 October 2018 Severe fatty liver disease boosts risk for liver cancer Reuters / 10 September 2018 Even light drinking may make fatty liver disease worse Reuters / 10 August 2018 ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E NAFLD Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds